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Aim: To conduct a survey in a representative cohort of ambulatory patients with stable, well managed chronic
heart failure (CHF) to discover their experiences of air travel.
Methods: An expert panel including a cardiologist, an exercise scientist, and a psychologist developed a series of
survey questions designed to elicit CHF patients' experiences of air travel (Appendix 1). The survey questions,
information sheets and consent forms were posted out in a self-addressed envelope to 1293 CHF patients.
Results: 464 patients (response rate 39%) completed the survey questionnaires. 54% of patients had travelled by
air since their heart failure diagnosis. 20% of all patients reported difﬁculties acquiring travel insurance. 65% of
patients who travelled by air experienced no health-related problems. 35% of patients who travelled by air
experienced health problems, mainly at the ﬁnal destination, going through security and on the aircraft. 27% of
all patients would not travel by air in the future. 38% of patients would consider ﬂying again if there were more
leg room on the aeroplane, if their personal health improved (18%), if they could ﬁnd cheaper travel insurance
(19%), if therewere lesswaiting at the airport (11%), or if there were lesswalking/fewer stairs to negotiate at the
airport (7%).
Conclusion: For most patients in this sample of stable, well managed CHF, air travel was safe.
© 2011 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Air travel, for business, family or vacation, is part of modern life in
Western societies. Lower costs, greater convenience of travel, and
greater longevitymean that older, retired people now frequently wish
to travel by air and many of these travellers will have chronic
ailments, including chronic heart failure (CHF). Cabin pressure in
modern airliners is set to that equivalent to an altitude of
approximately 8000 ft (2438 m) above sea level, which gives a partial
pressure of oxygen similar to that of breathing approximately 15%
oxygen at sea level. In healthy people, this leads to an increased
respiratory rate, and a reduction in arterial oxygen partial pressure
(PaO2) and arterial oxygen saturation [1–3]. Operation EVEREST III
suggested that altitude-induced hypoxaemia led to an increase in
heart rate, a decline in stroke volume, an increase in the atrial
component of left ventricular ﬁlling and a progressive rise in
pulmonary vascular resistance, all of which are of potential concern
in patients with CHF [4].
The assessment of ﬂight risk has received little attention and we
could identify few studies that have formally assessed the risk of air
travel in CHF.We showed that in 21 patients with CHF (NYHA class III/
IV), lying supine and breathing 15% oxygen for 1 h caused a drop in6.
C BY-NC-ND license.arterial oxygen saturation to 86% but patients remained asymptom-
atic throughout [5]. In a study of 38 patients with CHF, exercise testing
at sea level and simulated altitudes up to 3000 m using a fraction of
inspired oxygen (FiO2) of 14% [6] did not result in any angina,
arrhythmias or ECG evidence of ischaemia. At peak exercise at a
simulated altitude of 3000 m, the most symptomatic patients had the
largest decrease in both arterial oxygen saturation (SaO2, to 88%) and
exercise capacity (to 66% of that attained at simulated sea level). The
study concluded that patients with stable CHF who do not have effort-
induced arrhythmia or myocardial ischaemia can safely ascend to
altitudes of 3000 m. The effect of increased altitude on exercise
capacity becomes greater the more severe the exercise limitations at
sea level [6].
We hypothesised thatmanyCHF patientsmight not ﬂy due to health
concerns. We found no information regarding patients' experiences of
air travel, whether they wanted to travel by air, what factors encourage
or discourage them from air travel, and what problems they may have
encountered during ﬂight and at their destination. We conducted a
survey in a cohort of patients with well-treated, stable CHF to ﬁnd out
about their experiences of air travel.
2. Methods
The Hull and East Riding Ethics Committee approved the study, and all patients
provided informed consent prior to the survey. Patientswere recruited from a community
heart failure clinic serving the population of Hull and East Yorkshire. We contacted
patients with a previous diagnosis of heart failure deﬁned as the presence of appropriate
Table 1
Baseline clinical characteristics in patients with chronic heart failure (mean±SD or %).
Variables CHF patients
Age (years) 67.8±9.5
Males (%) 82
Body mass index (kg/m2) 28±6
Left ventricular ejection fraction (%) 37±5
Beta-blocker (%) 65
ACE-inhibitor (%) 51
Loop diuretic (%) 50
Aetiology of CHF
Ischaemic heart disease (%) 65
Dilated cardiomyopathy (%) 16
Unknown (%) 11
Hypertension (%) 5
Valvular (%) 3
Baseline data available in 174 of 464 patients (38% of total).
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dysfunction in the absence of any more likely cause [7]. All patients had left ventricular
systolic impairment on 2Dechocardiography carried out by oneof three trainedoperators.
An expert panel including a cardiologist (JGFC), an exercise scientist (LI), and a
psychologist (SN) developed a series of survey questions designed to elicit CHF
patients' experiences of air travel (Appendix 1). The survey questions, information
sheets and consent forms were sent together with a return self-addressed envelope to
1293 patients.
2.1. Statistical analysis
PASW (SPSS version 17.0) was used to analyse the data. Continuous variables are
presented as mean±SD, and categorical data are presented as percentages. An
arbitrary level of 5% statistical signiﬁcance was used throughout (two-tailed). We
conducted an age-adjusted logistic regression analysis to determine which element of
the journey was more likely to predict symptoms of breathlessness in our patients.
3. Results
464 CHF patients (response rate=39%) returned completed
survey questionnaires. Table 1 shows baseline clinical characteristics
of patients. 54% (252/464) of patients had travelled by air since their
heart failure diagnosis. Of those who had ﬂown, 21% had taken one
ﬂight, 25% 2 ﬂights, 21% 3 ﬂights, and 33% at least 4 ﬂights (Fig. 1). 60%
of patients who had ﬂown had visited countries within Europe, 12%
had ﬂown to Australia, and other longer-haul destinations included
North America (10%); Africa (6%); and Asia (6%) (Fig. 2). For patients
who had not travelled by air, reasons for not travelling included
medical concerns (33%), travel insurance problems (7%), and aFig. 1. Number of air travel jouproportion (27%) had no desire to travel abroad citing reasons such
as “too old”, “too much hassle”, and “don't like ﬂying” (Fig. 3).
20% of all patients (93/464) reported difﬁculties acquiring travel
insurance due to extra premiums being required. In some cases,
insurance companies refused to insure patients due to the nature of
their condition. 15% of patients who did ﬂy did not tell their insurer
about their cardiac condition, and 11% of patients travelled without
any insurance.
3.1. Health problems whilst travelling
65% (163/252) of patients who ﬂew experienced no health-related
problems. 35% (89/252) of patients who ﬂew experienced health-
related problems. Fig. 4 shows the location of the problems
experienced by the patients. 18% (46/252) experienced a problem at
one location; 6% (16/252) experienced problems at two locations; 5%
(13/252) experienced problems at three locations; 5% (12/252)
experienced problems at more than three locations.
Of the 89 patients who ﬂew and experienced health problems, 9%
(8/89) of patients reported problems going through security at the
airport due to pacemaker/ICD problem and breathlessness. During the
ﬂight, 9% (8/89) of patients experienced breathlessness, dizziness,
swollen ankles, headache, and chest pain. 3 of 8 patients used in-ﬂight
oxygen due to breathlessness. At the ﬁnal destination, 25% (22/89) of
patients complained of health-related cardiovascular problems
including fatigue, breathlessness, laboured walking, swollen ankles,
palpitations, angina, or their deﬁbrillator ﬁring (2 of 22 patients).
Following an age-adjusted logistic regression analysis, the ﬁnal
destination was a better predictor of self-reported symptoms of
breathlessness than other travel points (i.e. to security, to the ﬂight
gate, during air travel, during disembarkation) in our patients
(P=0.047; Hazard Ratio=0.16; 95% conﬁdence interval=0.30–
0.97).
3.2. Views on future air travel
27% (125/464) of all patients that we surveyed would not ﬂy in the
future. 32% (148/464) stated that it was too difﬁcult, 25% (116/464) of
patients wereworried about their health, 23% (107/464) had nowish to
travel byair, and11% (51/464) hadno insurance cover. 38% (176/464)of
all patients stated that they would consider ﬂying again if there were
more leg room/more comfort on the aeroplane during the ﬂight, if their
personal health improved (18%; 84/464), if they could ﬁnd cheaper
travel insurance (19%; 88/464), if there were less waiting at the airportrneys since ﬁrst diagnosis.
Fig. 2. Furthest air travel destinations reported by CHF patients.
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the airport (7%; 32/464) (Fig. 5).
46% (212/464) of all patients surveyed had not travelled by air since
their diagnosis. 37% (79/212)would considerﬂying in the future if there
were more leg room/comfort on the plane (38%; 30/79), if travel
insurancewere cheaper (22%; 17/79), if their health improved (18%; 14/
79), and if there were less waiting time at the airport (10%; 8/79). 54%
(252/464) of all patients surveyed had travelled since their diagnosis.
36% (91/252) would ﬂy again if there were more leg room/comfort on
the plane (37%; 34/91), if their health improved (20%; 18/91); if travel
insurance were cheaper (19%; 17/91), and if there were less waiting
time at the airport (13%; 12/91).
4. Discussion
Our study is the ﬁrst to gauge heart failure patients' experiences of
air travel. We have found that the majority of CHF patients who have
ﬂown since a diagnosis was made did not report any health-related
problems. This ﬁnding is in agreement with the few published
experimental studies which suggested that simulated ﬂights did not
produce complications in heart failure patients [5,6], and the recently
published expert consensus statement [8]. Indeed, we found that
there weremore health-related problems at the ﬁnal destination (25%
of ﬂying patients) than there were during ﬂight itself (9% of ﬂying
patients).
We have found that problems of air travel are not conﬁned to
hypoxia. Although we have not speciﬁcally asked about the following,
considerable exertion is required to walk to and from the plane at the
airport, especially if suitcases have to be carried. Take-off and landing
in particular may cause stress and anxiety. Implanted devices may
cause concerns at security points. Drug therapy may cause a variety of
problems including diuretics (toilet access), anti-coagulants (changeFig. 3. Reasons for not engaging in air travel.in diet), ACE inhibitors and aldosterone antagonists (ﬂuid balance due
to sweating and diarrhoea). Travel advice needs to recognise these
issues in CHF patients.
Recently, Smith and colleagues [8] produced an expert consensus
statement on ﬁtness to ﬂy for passengers with cardiovascular disease:
they concluded that in CHF, short-term (up to 1 h) exposure to a
hypoxic environment produces no signiﬁcant adverse effects (includ-
ing patients with NYHA class III/IV symptoms) at rest. Longer-term
hypoxic exposure (up to 7 h) can be tolerated in patients with mild-
to-moderate stable CHF [8]. The authors also reported that the aircraft
could be considered a “relatively alien, restrictive and hostile
environment” (p. ii1). The patients that we surveyed would appear
to agree. 37% of patients reported that they would only consider ﬂying
again if aircraft were more comfortable i.e. having more leg room.
In our study, 32% of patients reported that they would never ﬂy
again because it was too “difﬁcult”. Up to 40% of the population have
reported a fear of ﬂying [9] which may have been heightened by an
increased perception of terrorist activity since 2001 [10]. These factors
amongst others may have been concerns for our patients. 11% of
patients stated that theyweremore likely to ﬂy again if therewere less
waiting time at the airport terminal. Patients are often advised toFig. 4. Venn diagram showing the location of health-related problems experienced by
89 patients with CHF during air travel.
Fig. 5. Factors that would increase likelihood of future air travel in CHF patients.
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airline notice of special requirements such as wheelchair access or
supplementary oxygen [8]. Longer waiting times can cause frustration
and anger for some patients at the airport [11]. Strike and colleagues
[12] reported that anger is one of the precursors that can provoke
myocardial ischaemia in stressful situations. Further, 6% of patients
stated that the long walks around the airport caused breathlessness
and 7%would not ﬂy again due to the amount of walking required. The
amount of walking around the airport terminal, perhaps with heavy
luggage, and in conjunction with staircase-use, may cause deteriora-
tion in the patients' condition [8]. Whilst many airports offer excellent
transport services for “disabled” passengers—many patients may not
be aware of these services or how they canbook themprior to arrival at
the airport.
We recommend that more experimental work is required to ﬁnd
out if ﬂying is really safe in patients with CHF. Current ﬁndings would
appear to suggest that short- to longer-term hypoxic exposure is safe
in most stable heart failure patients.4.1. Limitations
Demographic data including age, sex, BMI, LVEF, drug therapy, and
aetiology of CHF was collected in 174 of 464 patients (38% of total)
due to a printing error with an initial batch of questionnaires.
A limitation of the postal survey is selection bias, often only
patients with strong positive or negative experiences will respond.
Within the survey we did not ascertain what family doctors had
actually told patients regarding their suitability for air travel. Lainscak
and colleagues [13] reported that recall of, and adherence to medical
advice was disappointing in a large pan-European cross-sectional
survey of 3261 CHF patients. Therefore, it is possible that some of our
patients may have misinterpreted medical advice from their family
doctor regarding their suitability to undertake air travel.5. Conclusions
Ours is the ﬁrst study to document CHF patients' experiences of air
travel. Health-related problems were only experienced in a minority
of patients, therefore, we can conclude that air travel is safe in stable,
well managed CHF patients. Future air travel experiences could be
improved if ﬂying were more comfortable, travel insurance were
cheaper, and there were less waiting time and less walking at airports.Conﬂict of interest
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Appendix 1
A pilot study examining risk associated with air travel in patients
with impaired hearts.
We would like you to consider the following questions, which will
ask you about your experiences of air travel. Please think about your
experiences SINCE you were diagnosed with your heart condition.
Thank you for your co-operation in this matter.
Please note the answers to the following questions will be kept
anonymous and your name will not be used unless we receive your
written consent.
1. Would you describe the severity of your health-related problem as:
NOT APPLICABLE MILD MODERATE SEVERE
(Please circle)
2. Have you travelled by air since you started taking water pills for
your heart condition?
YES NO
(Please circle)
If “YES”, how many times have you travelled? (Please circle)
a) 1
b) 2–3
c) 4–6
d) 7+
e) Where did you travel to?
…………………………………………………………— go to Question 3
If “NO”, please explain why (Please circle all that apply)
f) Too difﬁcult — go to Question 8
g) Worried about health — go to Question 8
h) Cannot get appropriate medical insurance cover — go to
Question 8
i) Other reasons — please specify — go to Question 8
…………………………………………………………………………
j) No desire to travel by air — please state why
……………………………………………………………………………
3. Medical insurance cover:
a) Did you tell your insurer you had a heart condition?
YES NO (Please circle)
b) Did you have trouble getting medical insurance cover?
YES NO (Please circle)
If “YES” please specify why?
…………………………………………………………………………
c) Who was your insurer?
…………………………………………………………………………
d) Did you decline to take out any medical insurance and travel
without cover?
YES NO (Please circle)
4. When you ﬂew, did you encounter any health-related problems:
a) Getting to the airport: YES NO (Please circle)
If “YES”, please specify
…………………………………………………………………………b) Getting through security: YES NO (Please circle)
If “YES”, please specify
…………………………………………………………………………
c) Getting to the ﬂight gate: YES NO (Please circle)
If “YES”, please specify
…………………………………………………………………………
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If “YES”, please specify
…………………………………………………………………………
e) During disembarkation: YES NO (Please circle)
If “YES”, please specify
…………………………………………………………………………
f) Travelling to your destination after disembarkation: YES NO
(Please circle)
If “YES”, please specify
…………………………………………………………………………
g) Whilst at your destination: YES NO (Please circle)
If “YES”, please specify
…………………………………………………………………………
5. Did you have to slow down or stop to catch your breath during any
of the above activities in Question 4?
YES NO (Please circle)
If so, which ones?
………………………………………………………………………………
6. Did you have to seek medical help at any time during your travel?
YES NO (Please circle)
If “YES”, please specify
………………………………………………………………………………
7. Did you have problems taking your medicines or with side effects
whilst away?
YES NO (Please circle)
If “YES”, please specify
………………………………………………………………………………
8. Would you consider travelling by air in the future?
YES NO (Please circle)
If “YES” please specify what would make the ﬂying process easier
and more enjoyable?
………………………………………………………………
If “NO”, please explain why by circling the appropriate response
a) Too difﬁcult
b) Worried about health
c) Cannot get appropriate medical insurance coverd) Other — please specify
…………………………………………………………………………
e) No wish to travel by air — please state why
…………………………………………………………………………
Date…………………………………………………………………………
Hospital Number…………………………………………………………
THANK YOU FOR YOUR PARTICIPATION IN THIS QUESTIONNAIREReferences
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